ENHANCED EXTERNAL COUNTERPULSATION EFFECTIVENESS ON CLINICAL PARAMETERS IN DIABETIC AND NON-DIABETIC CORONARY HEART DISEASE PATIENTS

Authors

  • Vikram Singh Department of Pharmacy, Lingaya’s University, Faridabad – 121 001, Haryana, India. http://orcid.org/0000-0002-8236-8241
  • Girija Kumari Department of Pharmacy, Lingaya’s University, Faridabad – 121 001, Haryana, India.
  • Bimal Chhajer Department of Preventive Cardiology, Science and Art of Living Heart Center (SAAOL), New Delhi – 110 030, Delhi, India.
  • Ashok K Jhingan Department of Medicine, Delhi Diabetes Research Center, New Delhi – 110 027, Delhi, India.
  • Saurabh Dahiya Department of Pharmacy, Lingaya’s University, Faridabad – 121 001, Haryana, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i7.25219

Keywords:

Enhanced external counterpulsation, Coronary heart disease, Angina, Dyspnea, Diabetes mellitus

Abstract

Objectives: The objectives of the study were to assess the effectiveness of enhanced external counterpulsation (EECP) treatment on clinical profile comprising physiological, biochemical, and clinical symptoms of diabetic and non-diabetic coronary heart disease (CHD) patients.

Methods: A pretest–posttest designed prospective study with 163 diabetic and non-diabetic CHD patients enrolled in Science and Art of Living Heart Center (SAAOL), New Delhi, India. Angina severity was assessed using Canadian Cardiovascular Society (CCS) angina classification scale and dyspnea status was assessed using medical research council (MRC) scale. The study subjects were followed up for 12 months. Statistical analysis was done using the SPSS v21 software. Descriptive analysis with sample t-test for two independent groups and paired sample t-test for EECP effectiveness within the group was done.

Results: A minute difference in body mass index mean (30.1±5.86–29.9±5.62 vs. 27.5±4.17–27.16±3.88) was observed in diabetic and non-diabetic CHD patients, but that was not statistically significant. A significant drop out in blood sugar fasting (166.7±41.9–150.1±23.7), blood sugar postprandial (204.7±64.4–173.2±41.2), and glycosylated hemoglobin (7.9±0.8 to 7.5±0.6) was also observed in diabetic CHD patients from baseline to 12th month after completion of EECP treatment with significant p<0.001, that may be due to EECP treatment. CCS angina classification score and MRC dyspnea score also significantly improved after EECP treatment.

Conclusion: EECP treatment may improve clinical symptoms of CHD and lower the blood glucose level in diabetic CHD patients. This treatment may be effective for CHD patients with diabetes mellitus.

Downloads

Download data is not yet available.

Author Biography

Vikram Singh, Department of Pharmacy, Lingaya’s University, Faridabad – 121 001, Haryana, India.

Professor & Head of Department Pharmacy

Lingaya's University

Faridabad Haryana -121002,

India

References

Pradeepa R, Mohan V. Prevalence of Type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr 2017;71:816-24.

Dorairaj P, Jeemon P, Roy A. Cardiovascular diseases in India current epidemiology and future directions. Circulation 2016;133:1605-20.

Andhuvan G. Development and validation of patient information leaflet for heart attack patients. Int J Pharm Pharm Sci 2016;8:381-3.

Li YW, Aronow WS. Diabetes mellitus and cardiovascular disease. J Clinic Exp Cardiol 2011;2:114.

Tolba MK, EL Khashab KA, Said AS. The effect of dipeptidyl eptidase-4 inhibitors on cardiovascular disease risk in Type 2 diabetes mellitus. Int J Pharm PharmSci 2017;9:254-9.

Iin P, Retnosari A, Rani S. Effectiveness of a medication booklet and counseling on treatment adherence in Type 2 diabetes mellitus patients. Int J App Pharm 2017;9:27-31.

Lama S, Nureddin H, Omar AG, Saleh M. Factors associated with hypertension prevalence and control among Lebanese Type 2 diabetic patients. Int J Pharm PharmSci 2016;8:153-9.

Rita S, Thobari JA, Irawan B, Dwiprahasto I. The blood pressure and therapy expenditure change due to hypertension comorbidity: A prospective analytical study in secondary care hospitals in Jogjakarta Indonesia. Int J Pharm Pharm Sci 2016;8:78-83.

Cara S, Julie ER. Effectiveness of telephone-delivered interventions for increasing physical activity levels in persons with Type 2 diabetes or hypertension: A systematic review. J Crit Rev 2015;2:6-11.

Rani RS, Madhavi G, Rao VR, Sahay BK. Risk factors for coronary heart disease in Type 2 diabetes mellitus. Indian J Clin Biochem 2005;20:75-80.

Maniarasu K, Muthunarayanan L. Prevalence of certain chronic complications of diabetes among Type 2 diabetic patients in rural population of Kancheepuram district, Tamil Nadu-a cross sectional study. Int J Med Public Health 2017;7:41-6.

Mohan V, Shanthirani C, Deepa M, Deepa R, Unnikrishnan R, Datta M. Mortality rates due to diabetes in a selected urban south Indian population-the Chennai Urban Population Study [CUPS-16]. J Assoc Phys India 2006;54:113-7.

Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: Cardiovascular disease in diabetes mellitus: Atherosclerotic cardiovascular disease and heart failure in Type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation 2016;133:2459-502.

Niharika V. Introduction to hyperlipidemia and its treatment: A review. Int J Curr Pharm Res 2017;9:6-14.

Boras J, Renar I, Car N, Željko M. Diabetes and coronary heart disease. Diabetol Croat 2002;31:199-208.

Bonetti PO, Holmes DR Jr., Lerman A, Barsness GW. Enhanced external counterpulsation for ischemic heart disease: What’s behind the curtain? J Am Coll Cardiol 2003;41:1918-25.

Tabary S, Yousefnejad K, Ziaee T, Fazli M. Assessment the clinical and para-clinical effects of enhanced external counter pulsation therapy in patients with coronary artery disease. Int J Med Invest 2015;4:245-8.

Beck DT, Casey DP, Martin JS, Sardina PD. Enhanced external counter pulsation reduces indices of central blood pressure and myocardial oxygen demand in patients with left ventricular dysfunction. Clin Exp Pharmacol Physiol 2015;42:315-20.

Shea ML, Richardconti C, Arora RR. An update on enhanced external counter pulsation. Clin Cardiol 2005;28:115-8.

Manchanda A, Soran O. Enhanced external counter pulsation and future directions step beyond medical management or patients with angina and heart failure. J Am Coll Cardiol 2007;50:1523-31.

Eslamian F, Aslanabadi N, Mahmoudian B, Shakouri SK. Therapeutic effects of enhanced external counter pulsation (EECP) on clinical symptoms, echocardiographic measurements, perfusion scan parameters and exercise tolerance test in coronary artery disease patients with refractory angina. Int J Med Sci Public Health 2013;2:187-95.

Nitu K, Mittal S, Kasliwal RR, Trehan N. Significant improvement in functional status and quality of life in heart failure patients who received EECP. J Clin Prev Cardiol 2013;2:8-16.

McCullough PA, Silver MA, Kennard ED. Impact of body mass index on outcomes of enhanced external counter pulsation therapy. Am Heart J 2006;15:9-13.

Subramanian R, Nayar S, Meyyappan C. Effect of enhanced external counter pulsation treatment on aortic blood pressure, arterial stiffness and ejection fraction in patients with coronary artery disease. J Clin Diagn Res 2016;10:30-4.

Anil K, Aronow WS, Vadnerkar A. Effect of enhanced external counter pulsation on clinical symptoms, quality of life, 6-minute walking distance, and echocardiographic measurements of left ventricular systolic and diastolic function after 35 days of treatment and at 1-year follow up in 47 patients with chronic refractory angina pectoris. Am J Ther 2009;16:116-8.

Kozdag G, Ertas G, Aygun F, Emre E, Kirbas A, Ural D, et al. Clinical effects of enhanced external counter pulsation treatment in patients with ischemic heart failure. Anadolu Kardiyol Derg 2012;12:214-21.

Linnemeier G, Rutter MK, Barsness G. Enhanced external counter pulsation for the relief of angina in patients with diabetes: Safety, efficacy and 1-year clinical outcomes. Am Heart J 2003;146:453-8.

Martin JS, Beck DT, Aranda JM Jr., Braith RW. Enhanced external counterpulsation improves peripheral artery function and glucose tolerance in subjects with abnormal glucose tolerance. J Appl Physiol 2012;112:868-76.

Li YW, Aronow WS. Diabetes mellitus and cardiovascular disease. J Clinic Exp Cardiol 2011;2:1-9.

Dockery F, Rajkumar C, Bulpitt CJ, Hall RJ, Bagger JP. Enhanced external counter pulsation does not alter arterial stiffness in patients with angina. Clin Cardiol 2004;27:689-92.

Braith RW, Conti CR, Nichols WW, Choi CY, Khuddus MA, Beck DT. Enhanced external counter pulsation improves peripheral artery flow-mediated dilation in patients with chronic angina a randomized sham-controlled study. Circulation 2010;122:1612-20.

Nichols WW, Estrada JC, Braith RW, Owens K, Conti RC. Enhanced external counter pulsation treatment improves arterial wall properties and wave reflection characteristics in patients with refractory angina. J Am Coll Cardiol 2006;48:1209-15.

Kumar S, Lahiri TK. Enhanced external counter pulsation as an effective nonsurgical solution for ischemic heart disease patients. Heart India 2017;5:55-60.

Beck DT, Martin JS, Casey DP, Avery JC, Sardina PD, Braith RW. Enhanced external counter pulsation improves endothelial function and exercise capacity in patients with ischaemic left ventricular dysfunction. Clin Exp Pharmacol Physiol 2014;41:628-36.

Ozlem S, Kennard ED, Kfoury AG. Two-year clinical outcomes after enhanced external counter pulsation therapy in patients with refractory angina pectoris and left ventricular dysfunction (report from the international EECP patient registry). Am J Cardiol 2006;97:17-20.

Pettersson T, Bondesson S, Cojocaru D, Ohlsson O, Wackenfors A, Edvinsson L. One year follow-up of patients with refractory angina pectoris treated with enhanced external counterpulsation. BMC Cardiovasc Disord 2006;6:1-7.

Loh PH, Louis AA, Windram J. The immediate and long-term outcome of enhanced external counter pulsation in treatment of chronic stable refractory angina. J Intern Med 2006;259:276-84.

Yavari M, Montazeri H. Effects of enhanced external counter pulsation on anginal symptoms and improvements in objective measures of myocardial ischaemia: Cardiovascular topic. Cardiovasc J Afr 2007;18:154-6.

Erdling A, Bondesson S, Patterson T, Evvinsson L. Enhanced external counter pulsation in treatment of refractory angina pectoris: Two year outcome and baseline factors associated with treatment failure. BMC Cardiovasc Disord 2008;18:39-43.

Lawson WE, Hui JC, Kennard ED, Barsness G, Kelsey SF. Predictors of benefit in angina patients one year after completing enhanced external counter pulsation: Initial responders to treatment versus non responders. Cardiology 2005;103:201-6.

Published

07-07-2018

How to Cite

Singh, V., G. Kumari, B. Chhajer, A. K. Jhingan, and S. Dahiya. “ENHANCED EXTERNAL COUNTERPULSATION EFFECTIVENESS ON CLINICAL PARAMETERS IN DIABETIC AND NON-DIABETIC CORONARY HEART DISEASE PATIENTS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 7, July 2018, pp. 151-7, doi:10.22159/ajpcr.2018.v11i7.25219.

Issue

Section

Original Article(s)

Most read articles by the same author(s)